FDA Likely To Allow Outcomes Studies Post-Approval For Fat Emulsion Drugs
Agency will probably clear products based on non-inferiority studies with nutrition endpoints, but ultimately wants clinical outcomes trials.
You may also be interested in...
Though it doesn’t have a formal labeling claim, olive-oil based parenteral nutrition drug provides marketing advantages compared to soybean fat emulsions drugs, while helping to ease shortage.
Voluntary hold on Propofol, Liposyn will negatively impact 2010 sales, though acquisition of Orchid will help make up the difference.
Regeneron President George Yancopoulos got in a screaming match at Milken conference, arguing paying for cures is a secondary problem that should be tackled once such products are developed. He also talked about how he believes tech companies are helping to create some of America’s health crises.